Genomic Classifier Tests Play Heterogeneous Role in Prostate Cancer Risk Classification

TUESDAY, Jan. 21, 2025-- For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk classification or treatment decisions, according to a review published online Jan. 21 in the...